(702) 683-8946

Monday - Friday 9am to 5pm

triangle
ad1

http://crweworld.com/assets/images/ad/content-delivery-solution.jpg

Our content delivery solution through CRWE WORLDCRWE Press Release and CRWE Tubegives corporations and businesses a vehicle to expand their exposure

Content Delivery Solution (Learn More)

ad3

http://crweworld.com/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

ad4

http://crweworld.com/assets/images/ad/submit_a_press_release.jpg

Submit Your Press Release/News to the CRWE WORLD Network for $14.95! Increase Visibility, Boost Your Business

www.CRWEPressRelease.com






Latest News Releases From The Newsroom

Strong Q1 Financial Performances: X Financial, Lizhi, Siyata Mobile; Weibo Beats Estimates

May 25th, 2023

In the first quarter of 2023, X Financial (NYSE: XYF) showcased a strong financial performance, demonstrating its continued growth and success. The company's total net revenue reached an impressive RMB1,004.9 million, marking a year-over-year inc. Read more

Splunk, ePlus and LiveRamp Beat Estimates, Digital Turbine Falls Short

May 24th, 2023

Splunk Inc.  (Nasdaq: SPLK), a leading provider of data analytics and monitoring solutions, has released its financial results for the fiscal first quarter of 2024. The company reported non-GAAP earnings per share (EPS) of $0.18, significantly b. Read more

Financial Results Triggering Stock Surges: VNET Group, NVIDIA, Modine Manufacturing, e.l.f. Beauty, Nutanix, Zuora

May 24th, 2023

VNET Group, Inc. (Nasdaq: VNET) has announced its financial results for the first quarter of 2023, exceeding market expectations. The company reported earnings per share (EPS) of $0.06, while the consensus projected a loss of $0.09 per share. This po. Read more

Disappointing Results in Mirati Therapeutics' SAPPHIRE Study and Annexon's ARCHER Trial Lead to Stock Declines

May 24th, 2023

Mirati Therapeutics, Inc. (Nasdaq: MRTX) revealed disappointing news regarding the SAPPHIRE study, as it failed to meet its primary goal of overall survival in the final analysis. The Phase 3 study aimed to assess the effectiveness of sitravatinib, i. Read more

Statement Regarding the Termination of Boston Scientific Corporation’s Attempted Acquisition of a Majority Stake in M.I. Tech Co., Ltd.

May 24th, 2023

Washington D.C. / CRWE PRESS RELEASE / May 24, 2023 -  In response to the announcement that Boston Scientific Corporation and non-vascular stent manufacturer M.I. Tech Co., Ltd. have terminated their $230 million purchase agreement, Federal. Read more

NVIDIA Down Before Earnings; Textron, Wave Life Sciences and Shopify Downgraded

May 24th, 2023

NVIDIA Corporation (Nasdaq: NVDA) is scheduled to announce its financial results for the first quarter of fiscal-year 2024 on Wednesday after the closing bell. Market participants are eagerly awaiting this announcement to gain insights into the compa. Read more

Enveric Biosciences Soars on EVM201 Series Potential, Immutep Surges on Clinical Trial Findings, Buy Rating for IDEAYA Biosciences

May 24th, 2023

Enveric Biosciences, Inc. (Nasdaq: ENVB) said that has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for another patent application involving its EVM201 Series The soon-to-issue patent, titled "C4-Carbox. Read more

Analysts' Perspective: Palo Alto Networks' PT Raised, Agilent Technologies' PT Lowered

May 24th, 2023

Palo Alto Networks, Inc. (Nasdaq: PANW) has seen a series of upward adjustments in its price target from various financial institutions. Deutsche Bank raised the price target from $210 to $225, Scotiabank increased it from $212 to $222, and Raymond J. Read more

Upgrades and Price Target Adjustments for Berry Global, Sherwin-Williams, Owens Corning, Organogenesis, and Workday

May 24th, 2023

In the latest market updates, several companies have received upgrades in their ratings and price targets. Berry Global Group, Inc. (NYSE: BERY) has been upgraded from Hold to Buy, with its price target raised from $69 to $73 at Truist. In pre-. Read more

Abercrombie & Fitch Beats Estimates, GigaCloud Technology Achieves Record Profitability, XPeng's Q1 Falls Short, and Autodesk Gets Market Perform Rating

May 24th, 2023

Abercrombie & Fitch Co. (NYSE: ANF) has released its first-quarter fiscal 2023 earnings results. The company reported adjusted earnings per share (EPS) of $0.39, surpassing the consensus estimate of a loss of $0.05 per share. This positive performanc. Read more